A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy

Caroline Schroten-Leof, Corinna de Riddler, Suzanne Reneman, Marije Crezee, Angus Dalgleish, Stephen Todryk, Chris Bangma, Robert Kraaij

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

A panel of cytokine-secreting RM-9 prostate cancer cells were tested as whole cell vaccines to determine their capacity to evoke an anti-prostate cancer immune response. In our model, vaccines secreting mGM-CSF or mIL-7 resulted in the highest increase in circulating T lymphocytes after vaccination, prolonged survival and, in a proportion of animals, tumor-free survival. Anti-tumor effects were more evident after a subcutaneous RM-9 challenge than after an intraprostatic challenge. However, when the RM-9/mGM-CSF cell line was used as intraprostatic tumor challenge, protection after RM-9/mIL-7 vaccination was restored.
Original languageEnglish
Pages (from-to)373-381
JournalCancer Immunology Immunotherapy
Volume58
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy'. Together they form a unique fingerprint.

Cite this